Ajinomoto Cambrooke, Inc.
Leiah Magliozzi is an experienced Client Service Associate and Reimbursement Specialist for Medical Food at Cambrooke Therapeutics, a role held since December 2013. Leiah has a background in pharmacy services as a National Certified Pharmacy Technician with CVS Caremark Corporation from December 2010 to April 2013. Prior roles include Office Manager at LiveWire Mobile and Verso Technologies, where responsibilities included managing inventory, purchasing supplies, and administrative support. Beginning as a receptionist at NMS Communications, Leiah eventually provided coverage as an Executive Assistant. Leiah holds a Medical Secretary, Billing & Coding degree from Middlesex Community College and an Associate's Degree in CAD/CADD Drafting and/or Design Technology/Technician from the same institution.
Ajinomoto Cambrooke, Inc.
Ajinomoto Cambrooke, Inc. formerly Cambrooke Therapeutics, Inc. (expansion of Cambrooke Foods) was founded in 2000 by Lynn and David Paolella, the parents of two children diagnosed with a rare disease called phenylketonuria (PKU). PKU is one of the few genetic diseases, which is managed almost entirely with nutritional intervention. The Paolellas’ goal in forming Cambrooke was simple - to develop improved nutritional therapeutic options for those with serious medical disorders. Today, Cambrooke produces medical formulas and foods for the management of a variety of medical conditions and we are continually innovating new nutritional options targeted at a wide array of diseases. Ajinomoto Cambrooke, Inc. - Leaders in Therapeutic Medical Nutrition. Cambrooke was the first medical foods company to launch a natural intact protein for the dietary management of phenylketonuria called Glytactin™ (modified glycomacropeptide). Cambrooke collaborates with academia and industry partners to transform early phase development projects in therapeutic nutrition into viable commercial products. Cambrooke employs scientific experts in the development, manufacturing and commercialization of nutritional therapeutics for patients with rare diseases. Cambrooke’s products are supported by clinical evidence for the nutritional management of medical needs before they are selected for commercialization. Cambrooke believes that both large and small patient populations are important when it comes to complex nutritional requirements.